ANZCTR search results

This study is evaluating the performance of Cxbladder tests in determining whether patients are at low or high risk of bladder cancer when presenting with blood in urine. Who is it for? You may be eligible to join this study if you are aged 18 years or over and are undergoing investigative cystoscopy at either the Princess Alexandra, Redland, Redcliffe or Queen Elizabeth II hospitals for investigation of recent (within the last 3 months) macroscopic or microscopic haematuria (i.e. blood in urine). Study details All participants in this study will undergo a Cxbladder urine diagnostic test as well as standard investigative cystoscopy. Results of both of these tests will then be compared in order to evaluate accuracy of the Cxbladder test. It is hoped that our study will determine the utility of the Cxbladder urine diagnostic test in an Australian clinical setting by demonstrating performance characteristics while also showing efficacy in clinical practice.

This pilot study will determine the effects of dignity therapy for palliative care patients with cancer. Who is it for? You may be eligible to join this study if you are aged 18 years or above and are a cancer patient with a palliative diagnosis. Study details All participants in this trial will be randomly allocated (by chance) to receive either dignity therapy with a cancer care coordinator who is trained in dignity therapy or standard palliative care. Participants will be followed-up at 4 weeks post intervention commencement with questionnaires to determine effect of treatment on levels of distress We hope to provide evidence that may allow us to introduce Dignity Therapy into the routine care of our patients in Mater Cancer Care Centre.

The aim of this study is to evaluate the safety and efficacy of a new medication called lipegfilgrastim to reduce a frequent complication of chemoimmunotherapy used to treat Non Hodgkin Lymphoma (NHL). Who is it for? You may be eligible to join this study if you are aged 18 years or older, have a confirmed diagnosis of NHL requiring chemoimmunotherapy, and are at risk of febrile neutropenia. Study details All participants in this study will receive preventive treatment with a drug called lipegfilgrastim. Lipegfilgrastim is a growth factor that stimulates the bone marrow to produce neutrophils, white cells that help fight infection. Lipegfilgrastim is administered via an injection under the skin 24-72 hours after each dose of chemotherapy. Nursing staff will administer the growth factor. In conjuction with your treating haematologist, you will be monitored until approximately 14-21 days you complete your last cycle of chemotherapy. There will also be a follow up phone call 3 months after completing the study. During the study, you will undergo medical consultation, physical examination and regular blood tests (all but one are additional to 'standard of care' for your condition) This trial will produce safety and efficacy data for this preventive treatment and may reduce a complication of NHL chemoimmunotherapy.

The aim of the Sydney 1000 Bowel Cancer Study is to collect a broad range of information from 1000 prospective bowel cancer patients recently diagnosed with any stage of colorectal cancer for up to 10 years. Who is it for? You may be eligible to join this study if you are aged 18 years or over and have a diagnosis of colorectal cancer (any stage). Study details The clinical research program involves the collection of clinical data at pre-defined time points detailing patients’ response to treatment, supplemented with patient reported outcome data collected from questionnaires during active treatment, regular follow-up (usually 5 years) and for the remainder of the study (up to 10 years). This longitudinal clinical data will be correlated with findings from the biological research program that involves the analysis of longitudinally collected biological samples (tumour, blood, and faeces) and experimental results. The resulting Sydney 1000 Bowel Cancer Study Biobank is expected to contain approximately 1,250 tissue specimens and 25,000 blood and faecal specimens from 1000 participant donors by 2029.

This is a study of two medications that may increase the sensitivity of metastatic melanomas to a currently used immunotherapy. Who is it for? You may be eligible for this study if you are 18 years or older and have an unresectable or metastatic melanoma which has primary resistance to previous immunotherapy (anti-PD1 therapy). Study details All participants in the study will receive a course of the two study drugs (azacitidine and carboplatin) for 8 weeks, before a ongoing course of immunotherapy (avelumub). Over the course of the study, blood samples and tumour biopsies will be taken to assess the treatment’s effect on the melanoma. It is hoped this study will provide evidence of these study substances increasing the sensitivity of melanomas to the anti-PDL1 antibody class of immunotherapy agents.

The aim of the research is to investigate if the option to choose a particular diet strategy as opposed to being prescribed a set strategy leads to greater weight loss. We hypothesise that freedom to choose the diet strategy will result in greater weight loss. This randomised parallel study and will include both men and women. Participants will be randomised to Choice or No Choice. The No Choice arm will be the 5 & 2 strategy (5 days of habitual eating with 2 very low energy intake days of 2000 - 3000kJ/day) compared with a Choice of 2 & 5 or continuous energy restriction (daily energy restriction between 4000-5000kJ/day). Participants will be asked to follow the diet for 8 weeks and attend the Sansom CTF at the start for randomisation and dietary instruction and every two weeks for 8 weeks. They will have height measured once and weight measured on each occasion. The first visit will take approximately 30 minutes and subsequent visits will take 15 minutes.

Clozapine is one of the most effective medications used for the treatment of schizophrenia. Up to 80% of patients treated with clozapine may complain of an increased secretion of saliva in the mouth (known as hypersalivation) as a result of being treated with clozapine. Hypersalivation may result in an overspill of saliva outside the mouth (known as drooling). Excessive production of saliva may disrupt sleep and speech, and cause aspiration pneumonia. Drooling is not pleasant and may damage the skin around your mouth. Atropine sulfate is one of the medications used most often in inpatient units in New South Wales-Australia to treat hypersalivation or drooling that is caused by clozapine. However, studies testing the effect of atropine are lacking. The aim from this study is to test the effect of atropine sulfate when administered under the tongue for the treatment of hypersalivation and/or drooling that is caused by clozapine. One sub-study to this study involves testing the chemical content of saliva by researchers in the ANZAC Research Institute at Concord Hospital. This research is designed by the mental health pharmacist Omar Mubaslat and overseen and supervised by consultant psychiatrist Professor Tim Lambert.

Updated criteria for the diagnosis of gestational diabetes (GDM) mean that larger numbers (approximately 18%) of women screened meet diagnostic criteria placing an increasing burden upon limited healthcare professional (HCP) resources. We hypothesise that while the 75g OGTT provides the standard for the diagnosis of GDM, continuous glucose monitoring (CGM) technology could provide a useful adjunct increasing efficiencies in patient care by more effectively triaging patients according to CGM profiles to identify those most likely to require intervention and expediting therapeutic decision-making by the health professional with the provision of more detailed data. All women with GDM diagnosed on OGTT between 24 to 28 weeks gestation will be offered retrospective CGM for a week, in addition to routine fingerprick glucose monitoring. They will also keep a record of HCP visits and time spent for the duration of the pregnancy. GDM management and maternal-fetal outcome data will be collected from medical records. Both OGTT (glucose levels) and CGM profiles (glucose levels and glycaemic variability) will be compared with subsequent therapeutic interventions, healthcare resource utilization and clinical outcomes to determine whether a set of criteria based on the glucose data obtained prior to 31 weeks can be employed to triage patients to either routine or more intensive follow up.

Postprandial (post-meal consumption) blood sugar level has been implicated in the development of obesity, type 2 diabetes and cardiovascular disease. It has been indicated that a rapid rate of rise followed by slower decline in the blood glucose levels post meal consumption are linked with fat deposition and adversely affect metabolic health. Curcumin, a bio-active ingredient obtained from the spice turmeric, is a potent anti-inflammatory agent, which is being now evaluated for its effects for controlling post meal blood sugar levels. Long chain omega 3 fatty acids (eicosapentanoic acid and docosahexaenoic acid) are established triglyceride lowering agents which are primarily obtained from fish or fish oil. The current purpose of this study is to evaluate the efficacy of a single dose of dietary supplements (curcumin and/or fish oil) on the post meal blood glucose rise in healthy individuals.

Hospitalization of older adults appears to result in functional decline mostly likely due to reduced activity level. Bed rest and low level of mobility were common occurrences during hospitalization of older adults. On average, these hospitalized older adults only spend 43 min a day standing or walking and 80% of their hospital stay is spent in bed. While it is acknowledged that bed rest and inactivity are detrimental for mobility and function, it is often observed that patients in the Geriatric Evaluation and Management (GEM) Unit are inactive during day hours. Physiotherapists play a crucial role in maximising patient mobility and independence through the prescription and delivery of exercise programmes. The type and intensity of exercise are important factors in determining patient outcome. Systematic reviews have found that weight bearing and targeted task specific exercises can improve balance and decrease falls in older people. Usual care physiotherapy provided in GEM unit consists of one-to-one individualised session. Exercises provided in groups via circuit training have shown benefits in improving balance in frail older people in the inpatient setting. Very little is known about the delivery of circuit class (therapy provided to more than 2 participants, involving a tailored intervention program with a focus on practice of functional task received in group setting in older people admitted to GEM unit who have multiple co-morbidities and reduced physical capacity. This study sought to determine if additional exercise provided via circuit training improves balance and functional outcome more than usual physiotherapy alone in adults undergoing rehabilitation in GEM unit.